Case Studies

Preclinical and Drug Discovery CRO

Explore our case studies to see how REPROCELL partners with clients to deliver data-rich, disease-relevant insights that accelerate drug discovery and de-risk development.

CASE STUDY – IPM: Achieve Regulatory Approval
CASE STUDY – Amgen: Avoid Species Differences
CASE STUDY – Roche: Eliminate Clinical Adverse Effects
CASE STUDY – Bionorica: Evaluating the Spasmolytic Effects of BNO 1095

On the REPROCELL blog

Latest

More on the blog

Inside the Sample Lifecycle: How Central Labs Protect Data from Collection to Analysis

Inside the Sample Lifecycle: How Central Labs Protect Data from Collection to Analysis

Explore how central laboratories safeguard data integrity throughout the sample lifecycle, from collection to analysis, ensuring reliable outcomes in research.

13 April 2026

Mapping the Competitive Landscape of Human Tissue-Based Drug Discovery

Mapping the Competitive Landscape of Human Tissue-Based Drug Discovery

Explore how REPROCELL leads in human tissue-based drug discovery, addressing market gaps and offering innovative, disease-relevant solutions for better therapeutic outcomes.

02 April 2026

5 Hard Truths About Bringing Stem Cell Therapies to the Clinic

5 Hard Truths About Bringing Stem Cell Therapies to the Clinic

Discover the essential truths behind developing clinical-grade stem cell therapies and learn how to navigate the complexities of GMP manufacturing successfully.

30 March 2026

Donor Variability in Ex Vivo Human Tissue Studies: Challenge, Feature, or Translational Advantage

Donor Variability in Ex Vivo Human Tissue Studies: Challenge, Feature, or Translational Advantage

Explore how donor variability in ex vivo human tissue studies enhances translational research by providing insights into patient heterogeneity and improving drug discovery.

12 March 2026